Rise in incidence of endometriosis is responsible for the notable growth of the endometriosis treatment market. As there are a handful of relieving procedures available, there is a scope for extensive research in this regard. Several clinical trials are being conducted with the objective of having a robust line of treatment in place.
WILMINGTON, Del., July 26, 2024 /PRNewswire/ -- The market for endometriosis treatment is projected to attain a value of US$ 3.1 billion by 2034. According to Transparency Market Research, the landscape was valued at US$ 1.4 billion in 2023. From 2024 to 2034, the market is anticipated to advance at a CAGR of 7.5%. Peritoneal and ovarian endometriosis treatments are well established, with laparoscopic cystectomy for ovarian endometriomas outperforming drainage and electrocoagulation.
Hormone therapies such as GnRH agonists and antagonists, aromatase inhibitors, and other hormonal medicines, are crucial in controlling endometriosis-related pain. Newer medications, such as GnRH antagonists like Elagolix and Letrozole, have showed promise, especially in terms of pain relief and fertility outcomes.
Despite the range of treatment choices, the market faces obstacles in providing effective long-term solutions that do not jeopardize fertility. Drugs such as Elagolix, which was licensed by the FDA in 2018, have considerable potential but require additional investigation, particularly in terms of its usage in pre-treatment prior to in vitro fertilization. Elagolix's ongoing clinical research (NCT04173169) is expected to provide useful insights once completed in September 2024.
Request a PDF Sample of this Report Now
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20834
The market is also looking into selective estrogen receptor modulators (SERMs), such as SR-16234, which show promise due to their unique receptor action but require further clinical validation. Furthermore, established treatments like Danazol are still being contested due to their negative effects, whereas medications like Gestrinone are less often used and unavailable in areas such as the United States.
Key Takeaways from the Market Study
- The global endometriosis treatment market is poised to garner a valuation of US$ 1.5 billion in 2024.
- From 2024 to 2034, the market is poised to expand more than 2x.
- Hormone therapy remains the most preferred treatment type for endometriosis.
- By drug class, gonadotropin-releasing Hormone (Gn-RH) agonists and antagonists to be most preferred.
Key Drivers and Trends
- The endometriosis treatment market is expected to rise, owing to developments in both surgical procedures and pharmaceutical innovations.
- The focus on finding medicines that do not impair fertility remains a major field of study, with hopeful implications for future market developments. As our understanding of endometriosis grows, the market will likely see more targeted and effective treatment choices, hence increasing the quality of life for affected women.
- There are various drugs in pipeline regarding endometriosis treatment. Furthermore, government and non-government agencies are also supporting research on this count.
- In February 2021, the DBT/Wellcome India Alliance announced that it would extend support to a major national research project called 'Endometriosis Clinical and Genetic Research in India (ECGRI)', which aimed to widen understanding of genetic risks and clinical phenotypes related to endometriosis.
Endometriosis Treatment Market Report Scope:
Report Coverage | Details |
Forecast Period? | 2024-2034 |
Base Year? | 2020-2022 |
Size in 2023 | US$ 1.4 Bn |
Forecast (Value) in 2034 | US$ 3.1 Bn |
Growth Rate (CAGR) | 7.5 % |
No. of Pages | 156 Pages |
Segments covered | By Treatment Type, By Drug Class, By Distribution Channel, By Region |
Unlock Growth Potential in Your Industry Download PDF Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20834
Key Regions Profiled
- North America dominates the endometriosis therapy landscape and the dominance is expected to remain unchanged during the forecast period. This is attributed to rise in incidence of endometriosis followed by increasing awareness regarding the same.
- For instance, as per the data published by the Office on Women's Health in 2021, endometriosis ends up affecting over 11% of women aged between 15 and 44.
- Asia Pacific's endometriosis treatment market growth is ascribed to a noticeable upswing in the number of patients suffering from endometriosis coupled with increasing R&D activities in this regard.
Competitive Landscape
Players in the endometriosis treatment landscape are seeking fast track approvals for their products from regulatory authorities. Given the highly complex nature of this treatment, providers have to comply with stringent guidelines before they make the said approach available to end users. Some prominent endometriosis treatment providers are given below:
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
- Ferring Pharmaceuticals
- Johnson & Johnson
- Myovant Sciences Ltd.
- Pfizer Inc.
- The Takeda Pharmaceutical Company Limited
- Lannett Co Inc.
- Teva Pharmaceutical Industries Ltd.
Key Developments
- In August 2022, Myovant Sciences and Pfizer announced that the U.S. FDA had approved MYFEMBREE meant for managing moderate-to-severe pain linked with endometriosis in the pre-menopausal women.
- In February 2022, ObsEva SA announced that it had inked a strategic licensing agreement with Theramex in order to extend support to commercialization of linzagolix across the markets out of the U.S.
- In January 2022, ObsEva announced positive results from Phase 3 EDELWEISS 3 trial of linzagolix, one of the oral Gn-RH antagonists, in women suffering from moderate-to-severe endometriosis-associated pain (EAP).
Segments Profiled
Treatment Type
- Pain Medication
- Hormone Therapy
Drug Class
- Hormonal Contraceptives
- Gonadotropin-releasing Hormone (Gn-RH) Agonists and Antagonists
- Progestin Therapy
- Aromatase Inhibitors
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=20834<ype=S
More Trending Report by Transparency Market Research:
- Infant Resuscitators Market - The global infant resuscitators market was valued at US$ 253.1 million in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2031, reaching over US$ 401.4 million by the end of 2031.
- Mechanical Thrombectomy Devices Market - The mechanical thrombectomy devices market was valued at US$ 1.1 billion in 2022. It is expected to grow at a CAGR of 6.4% from 2023 to 2031, reaching over US$ 1.8 billion by the end of 2031.
- Sanitization Robots Market- The sanitization robots market was valued at US$ 927.3 million in 2022. It is projected to advance at an impressive CAGR of 19.2% from 2023 to 2031, reaching over US$ 4.8 billion by 2031.
- Microcatheter Market - The global microcatheter market was valued at US$ 799.7 million in 2022. It is estimated to grow at a CAGR of 5.3% from 2023 to 2031, reaching approximately US$ 1.3 billion by the end of 2031.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube
Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/endometriosis-treatment-market-to-surge-to-us-3-1-billion-by-2034-innovations-in-surgical-procedures-and-fertility-preserving-medications-drive-market-growth--tmr-302207553.html
